Navigation Links
Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/5/2012

SAN DIEGO, Jan. 5, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at The Westin St. Francis in San Francisco, California. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview, including with regard to the company's recent resubmission of the new drug application for lorcaserin.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication of lorcaserin and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review, including the assignment of a PDUFA date, and approval is uncertain; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory review or approval; Arena's submission of a marketing authorization application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena Pharmaceuticals, Inc. Robert E. Hoffman, Vice President, Finance and Chief Financial Officer 858.453.7200  

 Investor Contact: Russo Partners, LLCMedia Contact: Russo Partners, LLCCindy McGee, Vice PresidentDavid Schull, President cindy.mcgee@russopartnersllc.comdavid.schull@russopartnersllc.com619.213.6995858.717.2310 

 www.arenapharm.com

  


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
2. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
3. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
4. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
5. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
6. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
7. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
8. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
9. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
11. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016   TraceLink Inc ., the World,s ... Life Sciences supply chain and eliminating counterfeit prescription ... Tjoapack has selected TraceLink,s serialization solutions to help ... the rapidly approaching serialization deadlines for the U.S. ... and the EU Falsified Medicines Directive (FMD) in ...
(Date:12/7/2016)...  Varian Medical Systems (NYSE: VAR ) ... to separate its Imaging Components business.  The separation is ... Varian stockholders of common stock in Varex Imaging Corporation, ... Imaging Components business.  As part of the separation, which ... of January 2017, Varian will receive an approximate $200 ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, ... three-dimensional biology company focused on delivering scientific and ... announced that Chairman and Chief Executive Officer ... VirtualInvestorConferences.com on Wednesday, December 14, 2016 at 1:00 ... who are not yet familiar with the Company, ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... When it came time to blow out ... Just 40 minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s ... the Weston teen the hospital’s 30th heart transplant recipient. , “He was playing at ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... planning services to families and business owners in the greater Dallas metropolitan area, ... the Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals ...
Breaking Medicine News(10 mins):